06:52 AM EDT, 10/14/2025 (MT Newswires) -- Takeda (TAK) has entered into a multiyear research collaboration with Nabla Bio to advance design of protein therapeutics, Nabla said Tuesday.

Under the terms of the deal, Nabla said it will receive double-digit millions in upfront and research cost payments. The company is also eligible to receive success-based payments that may surpass $1 billion in total, it said.

The deal includes de novo design of antibodies in parallel for multiple targets.